- Home
- NYC vs NXL Comparison
NYC vs NXL Comparison
Compare NYC & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NYC
- NXL
- Stock Information
- Founded
- NYC 2013
- NXL 2010
- Country
- NYC United States
- NXL United States
- Employees
- NYC N/A
- NXL N/A
- Industry
- NYC Real Estate
- NXL Medical Specialities
- Sector
- NYC Finance
- NXL Health Care
- Exchange
- NYC Nasdaq
- NXL Nasdaq
- Market Cap
- NYC 27.6M
- NXL 31.1M
- IPO Year
- NYC N/A
- NXL 2022
- Fundamental
- Price
- NYC $11.33
- NXL $1.75
- Analyst Decision
- NYC
- NXL Strong Buy
- Analyst Count
- NYC 0
- NXL 1
- Target Price
- NYC N/A
- NXL $5.00
- AVG Volume (30 Days)
- NYC 9.2K
- NXL 109.0K
- Earning Date
- NYC 05-09-2025
- NXL 05-09-2025
- Dividend Yield
- NYC N/A
- NXL N/A
- EPS Growth
- NYC N/A
- NXL N/A
- EPS
- NYC N/A
- NXL N/A
- Revenue
- NYC $61,570,000.00
- NXL $168,721.00
- Revenue This Year
- NYC $8.40
- NXL $79.59
- Revenue Next Year
- NYC $1.62
- NXL $334.65
- P/E Ratio
- NYC N/A
- NXL N/A
- Revenue Growth
- NYC N/A
- NXL 52.35
- 52 Week Low
- NYC $5.46
- NXL $0.53
- 52 Week High
- NYC $13.59
- NXL $4.49
- Technical
- Relative Strength Index (RSI)
- NYC 51.31
- NXL 41.01
- Support Level
- NYC $11.13
- NXL $1.56
- Resistance Level
- NYC $11.70
- NXL $1.81
- Average True Range (ATR)
- NYC 0.98
- NXL 0.22
- MACD
- NYC -0.05
- NXL 0.03
- Stochastic Oscillator
- NYC 45.72
- NXL 31.71
About NYC American Strategic Investment Co.
American Strategic Investment Co is an externally managed company that currently owns a portfolio of commercial real estate located within the five boroughs of New York City, majorly Manhattan. The Company's real estate assets consist of office properties and certain real estate assets that accompany office properties, including retail spaces and amenities.
About NXL Nexalin Technology Inc.
Nexalin Technology Inc designs and develops innovative neurostimulation products to uniquely and effectively help combat the ongoing global mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.